Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Companyâ€™s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physiciansâ€™ better risk-stratify pancreaticobiliary cancers using the Companyâ€™s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.

Employees

Sector

Healthcare Facilities & Services

More about the company

Market Cap	46.18M 40.26M 37.29M 34.91M 65.47M 4.36B 65.86M 442M 171M 2.14B 173M 170M 7.45B	P/E 2024	6.84x	P/E 2025	1.39x
Enterprise Value	44.86M 39.11M 36.22M 33.91M 63.59M 4.23B 63.98M 430M 167M 2.08B 168M 165M 7.23B	EV / Sales 2024	0.35x	EV / Sales 2025	0.11x
Free-Float	14.74%	Yield 2024 *	-	Yield 2025	-

13/05	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
31/03	Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
21/01	Interpace Biosciences Announces Preliminary and Unaudited Revenue Results for the Year 2025	CI
21/01	Interpace Biosciences, Inc. Provides Preliminary Unaudited Revenue Guidance for the Full Year of 2025 and Initiates Revenue Guidance for the Full Year of 2026	CI
04/12	Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners	CI
13/11	Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
13/11	Interpace Biosciences Q3 revenue down	RE
08/08/25	Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
09/05/25	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
09/05/25	Interpace Biosciences, Inc. Provides Revenue Guidance for the Full-Year 2025	CI
01/04/25	Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
10/01/25	Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk	CI
05/11/24	Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

13/05	Interpace Biosciences Announces First Quarter 2026 Financial and Business Results	AQ
31/03	Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results	AQ
21/01	Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure	AQ
04/12	Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners	AQ
13/11	Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results	AQ

Manager	Title	Age	Since
Thomas Burnell CEO	Chief Executive Officer	63	01/12/2020
Christopher McCarthy DFI	Director of Finance/CFO	34	21/04/2023
Nicole Massoll CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Stephen Sullivan CHM	Chairman	78	21/06/2016
Joseph Keegan BRD	Director/Board Member	73	01/01/2016
Fortunato Rocca BRD	Director/Board Member	64	22/01/2020

Interpace Biosciences, Inc. Stock Other OTC

Stocks

IDXG

US46062X3035

Healthcare Facilities & Services

Valuation: Interpace Biosciences, Inc.

Latest news : Interpace Biosciences, Inc.

Analysts' recommendations: Interpace Biosciences, Inc.

Press Releases: Interpace Biosciences, Inc.

Quotes and Performance

Managers and Directors: Interpace Biosciences, Inc.

Medical & Diagnostic Laboratories

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTERPACE BIOSCIENCES, INC.	+38.25%	+2.04%	-	-	46.18M
NATERA, INC.	+2.19%	+9.12%	+34.65%	+344.17%	33.14B
LABCORP HOLDINGS INC.	-1.44%	-3.88%	-2.31%	+10.52%	20.98B
SONIC HEALTHCARE LIMITED	+1.06%	-0.74%	-24.02%	-43.65%	6.95B
RADNET, INC.	+1.74%	-5.24%	-2.70%	+69.42%	4.23B
DR. LAL PATHLABS LIMITED	-1.63%	+2.14%	+12.34%	+47.15%	2.9B
GENEDX HOLDINGS CORP.	+4.59%	-1.52%	-11.93%	+836.67%	1.75B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	+0.37%	-2.73%	-8.76%	-67.10%	1.68B
DIAN DIAGNOSTICS GROUP CO.,LTD.	+0.39%	-7.83%	+34.22%	-30.62%	1.65B
FLEURY S.A.	-1.84%	-1.65%	+14.32%	-5.03%	1.58B
Average	+4.37%	-2.19%	+5.09%	+129.06%	8.32B
Weighted average by Cap.	+0.81%	+0.70%	+13.37%	+174.33%

	2024	2025
Net sales	46.93M 40.91M 37.89M 35.47M 66.53M 4.43B 66.93M 450M 174M 2.18B 176M 172M 7.57B	38.73M 33.77M 31.27M 29.28M 54.91M 3.65B 55.24M 371M 144M 1.8B 145M 142M 6.25B
Net income	6.7M 5.84M 5.41M 5.07M 9.5M 632M 9.56M 64.2M 24.88M 311M 25.16M 24.62M 1.08B	24.58M 21.43M 19.84M 18.58M 34.84M 2.32B 35.05M 235M 91.24M 1.14B 92.25M 90.27M 3.96B
Net Debt	4.4M 3.83M 3.55M 3.32M 6.23M 415M 6.27M 42.1M 16.32M 204M 16.5M 16.14M 709M	-1.32M -1.15M -1.07M -999K -1.87M -125M -1.89M -12.66M -4.91M -61.4M -4.96M -4.86M -213M